Anti-epidermal growth factor receptor monoclonal antibody plus palliative chemotherapy as a first-line treatment for recurrent or metastatic nasopharyngeal carcinoma.
Chen ChenYixin ZhouXuanye ZhangSha FuZuan LinWenfeng FangYunpeng YangYan HuangHongyun ZhaoShaodong HongLi ZhangPublished in: Cancer medicine (2020)
Anti-EGFR antibody plus chemotherapy achieved promising antitumor activity with a tolerable toxicity profile in RM-NPC. Thus, randomized clinical trials are warranted to compare the efficacy of chemotherapy with or without anti-EGFR antibody in these patients.
Keyphrases
- epidermal growth factor receptor
- tyrosine kinase
- small cell lung cancer
- monoclonal antibody
- advanced non small cell lung cancer
- locally advanced
- end stage renal disease
- ejection fraction
- newly diagnosed
- squamous cell carcinoma
- chronic kidney disease
- prognostic factors
- palliative care
- oxidative stress
- peritoneal dialysis
- chemotherapy induced
- clinical trial
- radiation therapy
- advanced cancer